Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation
570
0303 health sciences
Databases, Factual
Cell Survival
610
Antineoplastic Agents
Apoptosis
Surface Plasmon Resonance
Piperazines
3. Good health
Small Molecule Libraries
Chemistry
03 medical and health sciences
Drug Delivery Systems
Benzamides
Drug Discovery
MCF-7 Cells
Serine
Humans
RNA Interference
bcl-Associated Death Protein
Phosphorylation
Cell Proliferation
DOI:
10.1073/pnas.1804897115
Publication Date:
2018-10-11T18:45:18Z
AUTHORS (15)
ABSTRACT
Human BCL-2-associated death promoter (hBAD) is an apoptosis-regulatory protein mediating survival signals to carcinoma cells upon phosphorylation of Ser99, among other residues. Herein, we screened multiple small-molecule databases queried in a Laplacian-modified naive Bayesian-based cheminformatics platform and identified Petasis reaction product as site-specific inhibitor for hBAD phosphorylation. Based on apoptotic efficacy against mammary cells, N-cyclopentyl-3-((4-(2,3-dichlorophenyl) piperazin-1-yl) (2-hydroxyphenyl) methyl) benzamide (NPB) was potential lead compound. In vitro biochemical analyses demonstrated that NPB inhibited the specifically Ser99. observed exert this effect independently AKT kinase activities despite demonstration AKT-mediated BAD-Ser99 Using structure-based bioinformatics platform, exhibited predicted interactions with silico verified same by direct binding kinetics. reduced enhanced caspase 3/7 activity associated loss cell viability various human cancer lines derived from mammary, endometrial, ovarian, hepatocellular, colon, prostatic, pancreatic carcinoma. Furthermore, use xenograft model, it NPB, single agent, markedly diminished BAD tumor tissue significantly growth. Similar doses utilized acute toxicity studies mice did not exhibit significant effects. Hence, report models.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (74)
CITATIONS (43)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....